Scinai Immunotherapeutics Ltd. American Depositary Shares
SCNI
Closed
$0.25
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Key stats
Open
$0.27
Volume
91.83K
Market cap
$911.80K
Prev. close
$0.25
Impl / hst vl
-
Open interest
$0.00
$0.25
Day’s Range
$0.27
$0.24
52W Range
$1.12
Valuation
61
Valuation score
Undervalued
P/E
-
P/S
0.44
P/B
0.11
Current ratio
1.30
Debt / Equity
-0.17
ROE
-155.89%
Gross margin
-202.29%
Income growth
100.94%
FCF growth
34.05
Analysts estimates
Consensus rating
Buy
The average rating from top 4 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$714.00
The top 3 analysts forecasts that 12-month price may increase by 285,500.00%, with a low of $707.00 and a high of $735.00
$707.00
Low
$714.00
Avg
$735.00
High
Current price
Earnings
Q4 ‘25 revenue
$1.31M
Q4 ‘25 net income
-$8.31M
Revenue
Net income
Previous EPS
$8.00
Estimate EPS
-$6.32
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply